Sana Biotech Reports Q4 Net Loss Expansion, Plans IND Submission for SC451 in 2026, Stock Down 3.05%

Sana Biotechnology reported a Q4 net loss of $58.83 million, an increase from $49.07 million in the prior year. Adjusted net loss narrowed to $44.74 million, or $0.16 per share, from $54.79 million, or $0.23 per share. The firm plans to submit an IND for SC451 in 2026 and begin Phase 1 testing shortly thereafter. Sana's pipeline includes SC451 for type 1 diabetes and SG293 for blood cancers, with a cash runway expected to support operations through 2026.